# KLOW Peptide Reviews — Four-Component Evidence Appraisal > KLOW peptide is a four-component research blend of KPV, GHK-Cu, BPC-157 and TB-500. An evidence review of what each single-component study actually measured, the regulatory status, and what no trial has tested. None of its four components — KPV, GHK-Cu, BPC-157, or TB-500 — is FDA-approved for human use. The four-peptide combination has never been tested in a controlled study. This site reviews what the individual component research actually measured. ## In plain English KLOW peptide is a co-formulation of four research peptides — KPV, GHK-Cu, BPC-157, and TB-500 — dissolved together in one research vial. None of the four is approved by the FDA for human use, and the four-peptide combination itself has never been tested in any controlled study. What exists in the research literature is evidence for each individual component, studied separately, mostly in cells and animals. Each arm brings something different to the blend's theoretical rationale: KPV is an anti-inflammatory tripeptide studied in gut models; GHK-Cu is a copper-carrying tripeptide studied for collagen production and gene expression; BPC-157 is a 15-amino-acid peptide studied in tendon, gut, and angiogenesis models; and TB-500 is a short fragment of the protein thymosin beta-4, studied for wound closure and tissue repair. One important regulatory note: TB-500 (as the thymosin beta-4 fragment) is on the WADA prohibited list — banned in and out of competition for competitive athletes. This site appraises what the single-component literature found — and where [KLOW effects](/effects) people report experiencing begin and where the evidence actually ends. ## What is KLOW peptide? KLOW peptide is a co-formulated, lyophilized research blend of four chemically distinct peptides: KPV (Lys-Pro-Val, 342.44 Da), GHK-Cu (Gly-His-Lys copper(II) complex, 402.92 Da), BPC-157 (the 15-amino-acid Body Protection Compound, 1419.53 Da), and TB-500 (Ac-LKKTETQ, 889.02 Da). They do not form a single molecule or complex; they remain four separate peptides dissolved in one research vial. The most widely referenced research-vial composition is 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. GHK-Cu is the mass-dominant component at roughly 62.5% of the vial by weight. No FDA-approved or pharmacopeial KLOW combination product exists. For a full breakdown of what is [what is klow peptide](/what-is-klow), see the dedicated overview page. The [KLOW research](/research) page covers the single-component mechanism and study findings in detail. ## The four-arm mechanism — individual components The combination rationale is that the four peptides occupy largely non-overlapping nodes of a tissue-repair signaling network. KPV suppresses inflammatory transcription: nanomolar concentrations inhibit NF-kappaB (the master inflammatory switch) and MAPK signaling and reduce TNF-alpha, IL-6, and IL-1beta in human intestinal epithelial cells and mouse colitis models [1]. KPV reaches inflamed tissue preferentially via the PepT1 di/tripeptide transporter (SLC15A1), which is upregulated in inflamed gut. GHK-Cu modulates expression of approximately 31.2% of assayed human genes at a 50%-or-greater change threshold [2], with strong signals in extracellular-matrix remodeling (procollagen-I and procollagen-IV induction), antioxidant defense, and DNA-repair programs [3]. Plasma GHK levels decline from roughly 200 ng/mL at age 20 to roughly 80 ng/mL by age 60 [3], and topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid in placebo-controlled work [3]. BPC-157 activates the VEGFR2/PI3K/Akt/eNOS angiogenic pathway and modulates the nitric-oxide system in a manner partly resistant to L-NAME, upregulates the growth-hormone receptor in tendon fibroblasts, and has accelerated healing of a fully transected rat Achilles tendon across biomechanical and functional measures [4]. A 2025 first-in-human IV safety pilot (two adults, 10–20 mg by 1-hour infusion) found no adverse events and no measurable changes in safety biomarkers [5] — though this is a tiny sample, not an efficacy trial. TB-500 provides the LKKTET motif from thymosin beta-4 (Tbeta4), which sequesters G-actin (monomeric actin held in reserve) to accelerate cell migration and re-epithelialization. Full-length native Tbeta4 — in rat full-thickness wound models — increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, with increased wound contraction and collagen deposition, and as little as 10 pg stimulated keratinocyte migration 2-3-fold [6]. Importantly, these wound findings are for the native 43-amino-acid protein; the TB-500 fragment (Ac-LKKTETQ) has not been separately validated in comparable wound models. ## The central gap: no blend trial on record No controlled study has ever tested the four-peptide KLOW blend — against monotherapy, against any subset, or against placebo. Every claim about synergy between the four arms is a mechanistic extrapolation from the single-component literature, not direct blend evidence. A pharmacokinetic mismatch compounds the problem. BPC-157 has a very short elimination half-life (under approximately 30 minutes in rodent pharmacokinetic studies); the tripeptides KPV and GHK-Cu clear even faster; the TB-500 fragment behaves differently from full-length native thymosin beta-4. A single co-formulated vial cannot hold all four components at matched exposures. What 'one dose of KLOW' actually delivers in terms of simultaneous component concentrations at target tissues has not been characterized. A 2026 Sports Medicine systematic review of approved and unapproved peptide therapies for musculoskeletal conditions — including TB-500 and BPC-157 — concluded that many unapproved peptides show favorable outcomes in animal models but that human safety data are scarce, with potential for serious harm, and that these compounds operate largely outside regulatory oversight [7]. [KLOW results](/results) in the component literature are reviewed on that page. ## KLOW KLOW is the brand name for this four-peptide research co-formulation. It is distinct from GLOW (which lacks the KPV arm) and from WOLVERINE (a different peptide set). The 'K' in the name reflects the inclusion of KPV, the anti-inflammatory arm that differentiates KLOW from GLOW. KLOW is not a weight-loss or GLP-1 compound. None of its four components is a GLP-1 agonist or incretin; the blend has no established mechanism or evidence for metabolic weight management. Any framing of KLOW as a metabolic or weight-loss peptide is unsupported by the component literature. For regulatory status and safety context, see the [KLOW effects](/effects) page, which leads with the safety-regulatory appraisal, the community-reported signals labeled appropriately as anecdotal, and what the literature says about cautions. --- An independent evidence appraisal of four separate research peptide literatures — each finding kept to its own component, the blend's trial column left as the honest blank it is.